The ABILITY Diabetes Global trial finds the Abluminus DES+ stent fails non-inferiority to the XIENCE everolimus-eluting stent in diabetes, with higher repeat revascularisation and target-lesion failure. PICO summary and commentary.
Browsing: Cardiovascular
Cardiovascular outcomes, heart failure, cardio-renal protection, hypertension, and lipid-lowering trials in diabetes and endocrinology.
Summary: In Chinese middle-aged and elderly adults with prediabetes or early diabetes, purified anthocyanin supplementation (160, 320, and 640 mg/day…
A 12-week dose-response trial finds purified anthocyanin supplements up to 640 mg/day do not improve arterial stiffness, blood pressure, or cardiovascular risk in older adults with high blood sugar. PICO summary and commentary.
Summary: In individuals at risk for dementia with cardiometabolic features, intentional, non-pharmacological weight loss significantly reduced dementia risk as detected…
A small post hoc COMET subgroup finds SGLT2 inhibitor use is associated with about half as many eye injections in diabetic macular edema with high blood pressure, an exploratory finding from 29 patients. PICO summary and commentary.
Summary: In patients with diabetic macular edema (DME) and elevated office systolic blood pressure (OSBP), sodium-glucose cotransporter 2 inhibitors (SGLT2i)…
An observational ACCORD analysis finds higher weight-adjusted waist index is independently associated with more cardiovascular events, heart failure, and mortality in type 2 diabetes, outperforming BMI. PICO summary and commentary.
The SURPASS-CVOT trial finds tirzepatide noninferior but not superior to dulaglutide for major cardiovascular events in type 2 diabetes, confirming both incretin therapies are cardioprotective. PICO summary and commentary.
A prespecified SELECT analysis finds semaglutide’s cardiovascular benefit is largely independent of weight loss, with only a third mediated by waist reduction. PICO summary and commentary.
An 8-week RCT finds a hibiscus-inulin shot produces small reductions in lipid-glucose indices in overweight adults, but the authors stress these reflect analytical responsiveness, not proven clinical benefit. PICO summary and commentary.